tiprankstipranks
Shanghai Junshi Secures Oncology License Agreement
Company Announcements

Shanghai Junshi Secures Oncology License Agreement

Shanghai Junshi Biosciences Co., Ltd. Class H (HK:1877) has released an update.

Don't Miss Our Christmas Offers:

Shanghai Junshi Biosciences Co., Ltd. has entered into a significant license agreement to develop and commercialize two dual-targeting fusion proteins aimed at treating malignant tumors in Greater China. The company will co-own global rights to one of the products and will make an upfront payment, along with milestone and royalty payments, based on the progress of the project. This strategic move positions Junshi Biosciences to expand its oncology portfolio and potentially capitalize on lucrative markets.

For further insights into HK:1877 stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App